Purcell Ruth A, Aurelia L Carissa, Esterbauer Robyn, Allen Lilith F, Bond Katherine A, Williamson Deborah A, Trevillyan Janine M, Trubiano Jason A, Juno Jennifer J, Wheatley Adam K, Davenport Miles P, Nguyen Thi Ho, Kedzierska Katherine, Kent Stephen J, Selva Kevin John, Chung Amy W
Department of Microbiology and Immunology The Peter Doherty Institute for Infection and Immunity, University of Melbourne Melbourne VIC Australia.
Victorian Infectious Diseases Reference Laboratory (VIDRL) The Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.
Clin Transl Immunology. 2024 Feb 29;13(3):e1494. doi: 10.1002/cti2.1494. eCollection 2024.
Amino acid variations across more than 30 immunoglobulin (Ig) allotypes may introduce structural changes that influence recognition by anti-Ig detection reagents, consequently confounding interpretation of antibody responses, particularly in genetically diverse cohorts. Here, we assessed a panel of commercial monoclonal anti-IgG1 clones for capacity to universally recognise two dominant IgG1 haplotypes (G1m-1,3 and G1m1,17).
Four commercial monoclonal anti-human IgG1 clones were assessed via ELISAs and multiplex bead-based assays for their ability to bind G1m-1,3 and G1m1,17 IgG1 variants. Detection antibodies were validated against monoclonal IgG1 allotype standards and tested for capacity to recognise antigen-specific plasma IgG1 from G1m-1,3 and G1m1,17 homozygous and heterozygous SARS-CoV-2 BNT162b2 vaccinated ( = 28) and COVID-19 convalescent ( = 44) individuals. An Fc-specific -IgG detection antibody corroborated differences between hinge- and Fc-specific anti-IgG1 responses.
Hinge-specific anti-IgG1 clone 4E3 preferentially bound G1m1,17 compared to G1m-1,3 IgG1. Consequently, SARS-CoV-2 Spike-specific IgG1 levels detected in G1m1,17/G1m1,17 BNT162b2 vaccinees appeared 9- to 17-fold higher than in G1m-1,3/G1m-1,3 vaccinees. Fc-specific IgG1 and -IgG detection antibodies equivalently bound G1m-1,3 and G1m1,17 IgG1 variants, and detected comparable Spike-specific IgG1 levels between haplotypes. IgG1 responses against other human coronaviruses and influenza were similarly poorly detected by 4E3 anti-IgG1 in G1m-1,3/G1m-1,3 subjects.
Anti-IgG1 clone 4E3 confounds assessment of antibody responses in clinical cohorts owing to bias towards detection of G1m1,17 IgG1 variants. Validation of anti-Ig clones should include evaluation of binding to relevant antibody variants, particularly as the role of immunogenetics upon humoral immunity is increasingly explored in diverse populations.
超过30种免疫球蛋白(Ig)同种异型的氨基酸变异可能会引起结构变化,从而影响抗Ig检测试剂的识别,进而混淆抗体反应的解释,尤其是在基因多样化的队列中。在此,我们评估了一组商业单克隆抗IgG1克隆识别两种主要IgG1单倍型(G1m-1,3和G1m1,17)的能力。
通过酶联免疫吸附测定(ELISA)和基于多重微珠的检测方法,评估了四种商业单克隆抗人IgG1克隆结合G1m-1,3和G1m1,17 IgG1变体的能力。针对单克隆IgG1同种异型标准品验证检测抗体,并测试其识别来自G1m-1,3和G1m1,17纯合子和杂合子的接种严重急性呼吸综合征冠状病毒2(SARS-CoV-2)BNT162b2疫苗(n = 28)和新冠康复者(n = 44)的抗原特异性血浆IgG1的能力。一种Fc特异性抗IgG检测抗体证实了铰链区特异性和Fc特异性抗IgG1反应之间的差异。
与G1m-1,3 IgG1相比,铰链区特异性抗IgG1克隆4E3优先结合G1m1,17。因此,在G1m1,17/G1m1,17 BNT162b2疫苗接种者中检测到的SARS-CoV-2刺突蛋白特异性IgG1水平比G1m-1,3/G1m-1,3疫苗接种者中高9至17倍。Fc特异性IgG1和抗IgG检测抗体同等程度地结合G1m-1,3和G1m1,17 IgG1变体,并检测到两种单倍型之间相当的刺突蛋白特异性IgG1水平。在G1m-1,3/G1m-1,3受试者中,4E3抗IgG1同样难以检测到针对其他人类冠状病毒和流感的IgG1反应。
抗IgG1克隆4E3由于倾向于检测G1m1,17 IgG1变体而混淆了临床队列中抗体反应的评估。抗Ig克隆的验证应包括评估与相关抗体变体的结合,特别是在不同人群中对免疫遗传学在体液免疫中作用的探索日益增加的情况下。